Rifabutin, a rifamycin family member, is effective in treatment of tuberculosis in HIV-negative subjects. 6, 7, 8 Based on pharmacokinetic studies rifabutin has less of an effect than rifampicin on inducing hepatic enzymes, 9 and can be used in combination with PI-based ART regimens. count between the start and end of tuberculosis treatment were noted. Each patient was followed up for 24 months: outcomes during follow up, including death or recurrence, were recorded.
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Patients with known rifamycin and, or isoniazid resistance were excluded.
Patients were categorised as having either definite or presumptive tuberculosis, as previously described. 16 ART was defined as the use of at least three antiretroviral drugs including either a ritonavir-boosted PI (lopinavir or darunavir), or an NNRTI. Prescription of anti-tuberculosis medication and ART was based British HIV Association Guidelines, 2 and was at the discretion of individual physicians: treatment was self-administered in the majority of patients. All patients started standard four-drug tuberculosis therapy with isoniazid, pyrazinamide, ethambutol, and either rifabutin or rifampicin, except for two rifabutin-treated patients who started a quinolone in place of pyrazinamide (both had indeterminate pyrazinamide sensitivities and were fully sensitive to the other first-line medications). Rifampicin dosing was weight-based (450 or 600 mg once daily) and was given with a NNRTI. Rifabutin 450 mg once daily was used with efavirenz, 300 mg once daily with nevirapine, and 150 mg three times weekly was given with a ritonavir-boosted PI. All other anti-tuberculosis drugs were taken daily.
Data were analysed using STATA SE12 (Statacorp LP, College Station, Texas, USA). The  2 , Mann Whitney U, and Fisher's exact tests were used to compare rifabutin and rifampicin-treated groups. A p value of < 0.05 was considered significant. Ethics committee approval was not required as this was an observational evaluation of clinical outcomes.
A total of 171 HIV-infected patients were treated for tuberculosis with rifabutin (n=41) or rifampicin (n=130) and also received ART, including either an NNRTI or a ritonavir-boosted PI (Table 1) .
Patients treated with rifabutin and rifampicin were similar in age, gender, site of tuberculosis, and duration of treatment, but differed in ethnicity, HIV transmission category, and the interval between diagnosis of HIV and tuberculosis; p = 0.003, p = 0.051, and p = 0.001, respectively (Table 1) . At the end of tuberculosis treatment median CD4 increase, the proportion with an undetectable plasma HIV viral load (<50 copies/mL), and mortality were similar in rifabutin-and rifampicin- rifampicin-treated individuals had recurrent tuberculosis; two rifabutin-treated patients had died (one death was tuberculosis-related), and five rifampicin-treated patients had died (two deaths were tuberculosis-related).
In this two-centre, retrospective study of the treatment of tuberculosis in HIV infected adults, the major findings were that end of tuberculosis treatment median CD4 increases, the proportion with an undetectable plasma HIV viral load, and mortality were similar in rifabutin-and rifampicintreated individuals; by 24 months of follow up similar numbers of rifabutin-and rifampicin-treated individuals had recurrent tuberculosis, and had died. Overall, rifampicin-treated patients were more likely to have completed treatment than those who received rifabutin, and rifabutin-treated patients were more likely to develop IRIS.
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Comparison of the present data with previous studies of rifabutin-based treatment of tuberculosis in HIV infected individuals is hampered by their inconsistent use of ART and lack of 24 months outcome data. 13, 17, 18, 19 Singh et al, reported a retrospective observational study of outcomes from treatment of tuberculosis, using either rifabutin or rifampicin, in 141 HIV positive patients attending a single University-affiliated hospital in London, UK, over an 11 year period. 13 Patients who did not receive ART, those who received antiretroviral therapy regimens that did not include either a ritonavir-boosted PI or a NNRTI, and those who received ART (including either a ritonavir-boosted PI or a NNRTI) during treatment of tuberculosis were included. No differences in rates of adverse drug reaction, completion of tuberculosis treatment, or relapse of tuberculosis following completion of treatment were reported. 13 By contrast, the present study only included individuals who received ART containing either a ritonavir-boosted PI or an NNRTI during tuberculosis treatment, and all were treated using UK national guidelines for treatment of tuberculosis in HIV co-infection. 2 The present study has several limitations. Firstly, it is retrospective in design and there were only a relatively small number of rifabutin-treated individuals. Secondly, therapeutic drug monitoring data was not available for the majority of patients so optimal therapeutic doses could not be assessed.
Thirdly, many rifabutin-treated individuals were already receiving ART before anti-tuberculosis treatment was started, whereas rifampicin-treated patients were often ART-naive at the time of initiating anti-tuberculosis treatment. Finally, treatment was provided in a "developed world" setting and the observed outcomes may not be reproducible in a "developing world" setting where the majority of HIV/TB co-infection occurs.
In conclusion, the present study shows good outcomes from co-treatment of tuberculosis and HIV with either rifabutin or rifampicin and either NNRTI-or ritonavir-boosted PI-containing ART, however there is a clear need for prospective randomised clinical trials to identify effective, safe, evidence-based regimens for co-treatment of HIV and tuberculosis in patients needing ritonavirboosted PI-based ART, 20 as well as the optimal dosing schedule for rifabutin when coadministered with a ritonavir-boosted PI. 21 
